The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions.If you have any queries about the SPCs on our website then please e-mail vetinfo@hpra.ie


Rilexine DC 375 mg intramammary suspension for dry cows



Virbac S.A.VPA10988/115/001

Main Information

Trade NameRilexine DC 375 mg intramammary suspension for dry cows
Active SubstancesCephalexin benzathine
Dosage FormIntramammary suspension
Licence HolderVirbac S.A.
License Holder Address1ère avenue
2065 M LID
06516 Carros
France
Licence NumberVPA10988/115/001

Group Information

ATC CodeQJ51DB01 cefalexin
Therapeutic ClassAntibacterial
SpeciesCattle

Status

License statusAuthorised
Licence Issued08/07/2022
Legal StatusPOM: Prescription Only Medicine as defined in relevant national legislation

Documents

Summary of Product Characteristics *PDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
VariationsPDF Version

* The PDF document, together with the national-specific product information on this page, constitute the authorised SPC
« Back